Autonomy Bio is an early-stage biotech company focused on developing innovative therapies in aging biology and related fields. With a mission to create fixed-dose combination drugs that target the root causes of aging, the company aims to accelerate the time to clinical application and advocate for new regulatory pathways to recognize aging as an official indication. Backed by $15M in seed funding, Autonomy Bio is poised for significant growth and expansion in the coming 12 to 24 months.